TP53 and lung carcinoma: Somatic expression of these immunogens in studies by Platt et al. (15) did not block mutated Tp53 and Lkb1 from causing lung carcinoma but perhaps inflamed the modest immune surveillance against the subset of cells that were additionally edited to produce KrasG12D, which itself is a neoantigen (29), leading to a negative selection against these triple-mutated cells in the final tumors reported by Platt et al. (15).